Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Main Capital and Pointsharp in connection with their strategic acquisition of SecMaker
Mandate

Vinge has advised Main Capital and Pointsharp in connection with their strategic acquisition of SecMaker

July 08, 2021 Employment and Benefits Commercial Agreements M&A Intellectual Property

Pointsharp enables organizations to secure IT environments with a high-level of control for IT departments combined with an intuitive mobile user experience.

Pointsharp has a broad solution offering in the identity and access management market related to multi-factor authentication, secure access, user provisioning and password management. SecMaker is a leading security provider in complex system environments with a strong footprint in the healthcare and government sectors. The combination of Pointsharp and SecMaker creates a leading security software provider in the Swedish market with strong potential for future North-Western European growth.

Vinge’s team consisted of counsel Filip Öhrner and associates Vilhelm Rondahl, Gustav Lindgren (M&A), Ebba Svenburg (Employment), Karl-Hugo Engdahl (GDPR/IT), Rebecka Weitzberg (IP), Lisa Hörnqvist (Agreements) and VDR assistant Carl Bruneheim (VDR).

Related

Vinge advises Sobro on its investment in Västkustens Konstruktionsbyrå

 Västkustens Konstruktionsbyrå has decided to broaden its ownership structure by bringing in Sobro as a new co-partner and majority shareholder. The founders will remain with the company as the CEO and CTO respectively, and as significant shareholders. Västkustens Konstruktionsbyrå is an engineering consultancy company based in Gothenburg with cutting-edge expertise in project management, civil engineering and design.
April 23, 2026

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026